Foundation Medicine, Inc. [FMI] to Ring The NASDAQ Stock Market Opening Bell

ADVISORY, Feb. 10, 2014 (GLOBE NEWSWIRE) --

What:

Foundation Medicine, Inc. [FMI], a molecular information company dedicated to a transformation in cancer care, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Dr Michael Pellini, CEO will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Tuesday, February 11, 2014 – 9:15 a.m. to 9:30 a.m. ET

Contact:

Matt Clawson

(949) 474-4300

matt@allencaron.com

NASDAQ MarketSite:

Christine Barna

(646) 441-5310

Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit our Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A LiveStream of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live

Or

http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.                           

About Foundation Medicine, Inc. [FMI]:

Foundation Medicine® (Nasdaq:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify the molecular alterations in a patient's tumor and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-

In This Story

NDAQ